{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:57:49Z","timestamp":1793386669619,"version":"4.5.0"},"reference-count":46,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"Background:<\/jats:title>Melasma is a chronic skin condition that adversely impacts quality of life. Although many therapeutic modalities are available there is no single best treatment for melasma. Oral tranexamic acid has been used for the treatment of this condition but its optimal dose is yet to be established.<\/jats:p><\/jats:sec>Objectives:<\/jats:title>We used network meta-analysis to determine the optimal dose of oral tranexamic acid for the treatment of melasma.<\/jats:p><\/jats:sec>Methods:<\/jats:title>We conducted a comprehensive search of all studies of oral tranexamic acid for the treatment of melasma up to September 2020 using PubMed, EMBASE and the Cochrane Library database. The quality of the studies was evaluated using the Jadad score and the Cochrane\u2019s risk of bias assessment tool. Only high quality randomised controlled trials were selected. Some studies lacked standard deviation of changes from baseline and these were estimated using the correlation coefficient obtained from another similar study.<\/jats:p><\/jats:sec>Results:<\/jats:title>A total of 92 studies were identified of which 6 randomized controlled trials comprising 599 patients were included to form 3 pair-wise network comparisons. The mean age of the patients in these studies ranged from 30.3 to 46.5 years and the treatment duration ranged from 8 to 12 weeks. The Jadad scores ranged from 5 to 8.<\/jats:p>The optimal dose and duration of oral tranexamic acid was estimated to be 750 mg per day for 12 consecutive weeks.<\/jats:p><\/jats:sec>Limitations:<\/jats:title>Some confounding factors might not have been described in the original studies. Although clear rules were followed, the Melasma Area and Severity Index and the modified Melasma Area and Severity Index were scored by independent physicians and hence inter-observer bias could not be excluded.<\/jats:p><\/jats:sec>Conclusion:<\/jats:title>Oral tranexamic acid is a promising drug for the treatment of melasma. This is the first network meta-analysis to determine the optimal dose of this drug and to report the effects of different dosages. The optimal dose is 250 mg three times per day for 12 weeks, but 250 mg twice daily may be an acceptable option in poorly adherent patients. Our findings will allow physicians to balance drug effects and medication adherence. Personalized treatment plans are warranted.<\/jats:p><\/jats:sec>","DOI":"10.25259\/ijdvl_530_2021","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T08:50:58Z","timestamp":1660985458000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The optimal dose of oral tranexamic acid in melasma: A network meta-analysis"],"prefix":"10.25259","volume":"89","author":[{"given":"Wei-Jen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Yin","family":"Wu","sequence":"additional","affiliation":[{"name":"University of Taipei and Taipei City Hospital and National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Liang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yao","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Zhongxing Branch, Taipei City Hospital, Taipei, Taiwan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chu","family":"Chie","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"10.25259\/IJDVL_530_2021\/ref-1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1590\/S0365-05962009000600008","article-title":"[Physiopathology of melasma]","volume":"84","author":"Miot","year":"2009","journal-title":"An Bras Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","article-title":"Melasma: An up-to-date comprehensive review","volume":"7","author":"Ogbechie-Godec","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_530_2021\/ref-3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2010.12.046","article-title":"Melasma: a comprehensive update: Part I","volume":"65","author":"Sheth","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0738-081X(96)00108-3","article-title":"Physiological changes in the skin during pregnancy","volume":"15","author":"Elling","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1468-3083.2011.04430.x","article-title":"Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women","volume":"27","author":"Tamega Ade","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_530_2021\/ref-6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/pcmr.12404","article-title":"Recent progress in melasma pathogenesis","volume":"28","author":"Lee","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.25259\/IJDVL_530_2021\/ref-7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/ijms17060824","article-title":"Heterogeneous pathology of melasma and its clinical implications","volume":"17","author":"Kwon","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJDVL_530_2021\/ref-8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.12049","article-title":"Melasma pathogenesis and influencing factors-An overview of the latest research","volume":"27","author":"Passeron","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_530_2021\/ref-9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.sder.2009.04.001","article-title":"Management of hyperpigmentation in darker racial ethnic groups","volume":"28","author":"Grimes","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"10.25259\/IJDVL_530_2021\/ref-10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaad.2011.06.001","article-title":"Melasma: A comprehensive update: Part II","volume":"65","author":"Sheth","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ajd.12290","article-title":"Melasma: Clinical diagnosis and management options","volume":"56","author":"Rodrigues","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13555-014-0064-z","article-title":"Evidence-based treatment for melasma: Expert opinion and a review","volume":"4","author":"Shankar","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_530_2021\/ref-13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/jocd.12026","article-title":"Tranexamic acid: An important adjuvant in the treatment of melasma","volume":"12","author":"Tse","year":"2013","journal-title":"J Cosmet Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1248\/jhs.53.389","article-title":"Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium","volume":"53","author":"Maeda","year":"2007","journal-title":"J Health Sci"},{"key":"10.25259\/IJDVL_530_2021\/ref-15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1684\/ejd.2010.0912","article-title":"Tranexamic acid can treat ultraviolet radiation-induced pigmentation in guinea pigs","volume":"20","author":"Li","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1011-1344(98)00212-7","article-title":"Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation","volume":"47","author":"Maeda","year":"1998","journal-title":"J Photochem Photobiol B"},{"key":"10.25259\/IJDVL_530_2021\/ref-17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1538-7836.2004.00694.x","article-title":"Plasminogen regulates pro-opiomelanocortin processing","volume":"2","author":"Wang","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.25259\/IJDVL_530_2021\/ref-18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12465","article-title":"Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies","volume":"30","author":"Taraz","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_530_2021\/ref-19","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/DSS.0000000000001518","article-title":"Oral tranexamic acid for the treatment of melasma: A review","volume":"44","author":"Bala","year":"2018","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_530_2021\/ref-20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: A clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_530_2021\/ref-22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthetic Plast Surg"},{"key":"10.25259\/IJDVL_530_2021\/ref-23","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1111\/ajd.12474","article-title":"Oral tranexamic acid lightens refractory melasma","volume":"58","author":"Tan","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4103\/0019-5154.164416","article-title":"Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial","volume":"60","author":"Padhi","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3109\/09546634.2011.643220","article-title":"Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser","volume":"24","author":"Cho","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_530_2021\/ref-27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/dsu.12060","article-title":"Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: A randomized, prospective trial","volume":"39","author":"Shin","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_530_2021\/ref-28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1524-4725.2006.32133.x","article-title":"Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial","volume":"32","author":"Lee","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_530_2021\/ref-29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: Combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_530_2021\/ref-30","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","article-title":"Network meta-analysis for comparing treatment effects of multiple interventions: An introduction","volume":"34","author":"Catala-Lopez","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.25259\/IJDVL_530_2021\/ref-31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.25259\/IJDVL_530_2021\/ref-32","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_530_2021\/ref-33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.25259\/IJDVL_530_2021\/ref-34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/XEB.0000000000000140","article-title":"A generalized pairwise modelling framework for network meta-analysis","volume":"16","author":"Doi","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"10.25259\/IJDVL_530_2021\/ref-35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.25259\/IJDVL_530_2021\/ref-36","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Stat Med"},{"key":"10.25259\/IJDVL_530_2021\/ref-37","first-page":"204","article-title":"Comparison of efficacy and safety of topical hydroquinone 2% and oral tranexamic acid 500 mg in patients of melasma","volume":"27","author":"Rafi","year":"2018","journal-title":"J Pak Assoc Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-38","article-title":"MetaXL User Guide Australia: EpiGear International Pty Ltd","author":"Barendregt","year":"2011"},{"key":"10.25259\/IJDVL_530_2021\/ref-39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1684\/ejd.2018.3494","article-title":"Analysis of the effect of different doses of oral tranexamic acid on melasma: A multicentre prospective study","volume":"29","author":"Zhu","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3126\/kumj.v10i4.10993","article-title":"Oral tranexamic acid for the treatment of melasma","volume":"10","author":"Karn","year":"2012","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"key":"10.25259\/IJDVL_530_2021\/ref-41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/jocd.12291","article-title":"Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: A parallel-group, assessor-and analyst-blinded, randomized controlled trial with a short-term follow-up","volume":"16","author":"Lajevardi","year":"2017","journal-title":"J Cosmet Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/jocd.12830","article-title":"Evaluation of oral tranexamic acid in the treatment of melasma","volume":"18","author":"Colferai","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-43","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1111\/jdv.16598","article-title":"Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: A prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study","volume":"34","author":"Minni","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_530_2021\/ref-44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ajd.13267","article-title":"Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma","volume":"61","author":"Shihab","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","article-title":"A review of laser and light therapy in melasma","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.25259\/IJDVL_530_2021\/ref-46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3629.3629","article-title":"Tranexamic acid is a weak provoking factor for thromboembolic events: A systematic review of the literature","author":"Dyba","year":"2013","journal-title":"American Society of Hematology Washington, DC"},{"key":"10.25259\/IJDVL_530_2021\/ref-47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/the-optimal-dose-of-oral-tranexamic-acid-in-melasma-a-network-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/the-optimal-dose-of-oral-tranexamic-acid-in-melasma-a-network-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T23:50:18Z","timestamp":1700956218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/the-optimal-dose-of-oral-tranexamic-acid-in-melasma-a-network-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":46,"alternative-id":["10.25259\/IJDVL_530_2021"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_530_2021","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"189"}}